Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 7/20 | 0.70 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | SCN1A | P35498 | 2/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CCR8 | P51685 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7457681 | 0.89 | NPY5R (0.64) | NSD2NPY5RCA9SCN1ASCN2A | |
| SCHEMBL1684841 | 0.87 | TSHR (0.65) | NSD2NPY5RCA12CA9CCR8 | |
| SCHEMBL8890912 | 0.85 | NPY5R (0.64) | NSD2NPY5RCA9SCN1ASCN2A | |
| SCHEMBL29162296 | 0.84 | NSD2 (0.73) | NSD2NPY5RALDH1A1KDM4E | |
| SCHEMBL8913909 | 0.84 | KMT2A (0.66) | NSD2NPY5RCYP3A4MAPK1 | |
| SCHEMBL4487552 | 0.84 | NSD2 (0.63) | NSD2NPY5RCA12CA9ALDH1A1 | |
| SCHEMBL3701345 | 0.84 | NSD2 (0.72) | NSD2SCN1ASCN2ASCN3AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4493664 | 0.83 | NSD2 (0.64) | NSD2NPY5RCA12CA9SCN1A | |
| SCHEMBL4441197 | 0.83 | NSD2 (1.00) | NSD2NPY5R | |
| SCHEMBL4483905 | 0.83 | NSD2 (0.69) | NSD2CA12CA9ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093960-A1 | METHOD OF INHIBITING APOLIPOPROTEIN-E EXPRESSION WHILE INCREASING EXPRESSION OF AT LEAST ONE OF LDL-RECEPTOR PROTEIN OR ABCA1 PROTEIN COMPRISING ADMINISTERING A SMALL COMPOUND | LDLR, APOB, NR1H2 | NSD2 4015/4885NPY5R 4379/4885CA12 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.